Jazz Pharmaceuticals plc has completed its previously announced acquisition of Chimerix Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. “Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,” said Bruce Cozadd, chairman and CEO of Jazz. The addition of dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffus...